Loading...

Susan Groshen, PhD

Title(s)Retired Faculty
AddressNTT 4425A 1441 Eastlake Avenue
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Groshen is involved in the evaluation of new drugs and therapeutic strategies for treating cancer. As the statistician overseeing the clinical trials program at the USC/Norris Comprehensive Cancer Center, Dr. Groshen is responsible for statistical and design issues and is involved in the planning of data management. As studies are completed, she is responsible for statistical analysis of the results.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urol Oncol. 2021 Feb 06. PMID: 33563539.
      View in: PubMed   Mentions:    Fields:    
    2. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 Jan 10. Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. PMID: 33423090.
      View in: PubMed   Mentions:    Fields:    
    3. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2020 Jun 15; 17(1):189. Gilmore W, Lund BT, Li P, Levy AM, Kelland EE, Akbari O, Groshen S, Cen SY, Pelletier D, Weiner LP, Javed A, Dunn JE, Traboulsee AL. PMID: 32539719.
      View in: PubMed   Mentions:    Fields:    
    4. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clin Cancer Res. 2019 12 01; 25(23):7004-7013. Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM. PMID: 31481504.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    5. Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. Pharm Stat. 2019 11; 18(6):659-670. Ji L, Lewinger JP, Krailo M, Groshen S, Conti DV, Asgharzadeh S, Sposto R. PMID: 31237419.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    7. Biliary-Enteric Drainage vs Primary Liver Transplant as Initial Treatment for Children With Biliary Atresia. JAMA Surg. 2019 01 01; 154(1):26-32. LeeVan E, Matsuoka L, Cao S, Groshen S, Alexopoulos S. PMID: 30208381.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. Int J Radiat Oncol Biol Phys. 2019 05 01; 104(1):50-60. Ballas LK, Luo C, Chung E, Kishan AU, Shuryak I, Quinn DI, Dorff T, Jhimlee S, Chiu R, Abreu A, Jennelle R, Aron M, Groshen S. PMID: 30605751.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    9. Contrast-Enhanced Ultrasound Imaging of Breast Masses: Adjunct Tool to Decrease the Number of False-Positive Biopsy Results. J Ultrasound Med. 2019 Sep; 38(9):2259-2273. Lee SC, Tchelepi H, Grant E, Desai B, Luo C, Groshen S, Hovanessian-Larsen L. PMID: 30597640.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. BMC Cancer. 2018 Oct 11; 18(1):970. Brunette LL, Mhawech-Fauceglia PY, Ji L, Skeate JG, Brand HE, Lawrenson K, Walia S, Chiriva-Internati M, Groshen S, Roman LD, Kast WM, Da Silva DM. PMID: 30309325.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    11. The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study. Adv Radiat Oncol. 2019 Jan-Mar; 4(1):96-102. Kraus RD, Barsky A, Ji L, Garcia Santos PM, Cheng N, Groshen S, Vapiwala N, Ballas LK. PMID: 30706016.
      View in: PubMed   Mentions:
    12. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149. DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. PMID: 30093449.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    13. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clin Cancer Res. 2018 12 15; 24(24):6150-6159. Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. PMID: 30082475.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    14. Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 08; 16(4):e719-e727. Ballas LK, Kraus R, Ji L, Groshen S, Stern MC, Gill I, Quinn DI, Chung E, Abreu A, Hamilton AS. PMID: 29483045.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Improvement in the Outcomes of MELD = 40 Liver Transplantation: An Analysis of 207 Consecutive Transplants in a Highly Competitive DSA. Transplantation. 2017 10; 101(10):2360-2367. Nekrasov V, Matsuoka L, Kaur N, Pita A, Whang G, Cao S, Groshen S, Alexopoulos S. PMID: 28319564.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. Clin Genitourin Cancer. 2017 Sep 06. PMID: 28958673.
      View in: PubMed   Mentions:    Fields:    
    17. A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):742-749. PMID: 28668277.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    18. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. PMID: 28559462.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    19. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. J Hepatol. 2017 09; 67(3):517-525. PMID: 28483678.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant Kras-driven pancreatic tumorigenesis in mice. Proc Natl Acad Sci U S A. 2017 05 16; 114(20):E4020-E4029. Shen J, Ha DP, Zhu G, Rangel DF, Kobielak A, Gill PS, Groshen S, Dubeau L, Lee AS. PMID: 28461470.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    21. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clin Cancer Res. 2017 Aug 15; 23(16):4550-4555. PMID: 28420721.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    22. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017 05; 77:13-20. PMID: 28347919.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    23. No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses. Clin Breast Cancer. 2017 11; 17(7):510-515. Bian SX, Korah MP, Whitaker TR, Ji L, Groshen S, Chung E. PMID: 28412326.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017 02 15; 9(377). PMID: 28202779.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    25. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer. J Ultrasound Med. 2017 May; 36(5):901-911. PMID: 28150325.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    26. Effects of Prolonged GRP78 Haploinsufficiency on Organ Homeostasis, Behavior, Cancer and Chemotoxic Resistance in Aged Mice. Sci Rep. 2017 02 01; 7:40919. PMID: 28145503.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    27. Effects of recipient size and allograft type on pediatric liver transplantation for biliary atresia. Liver Transpl. 2017 02; 23(2):221-233. PMID: 27862929.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Association of high microvessel avß3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2017 Aug 08; 8(32):52193-52210. PMID: 28881723.
      View in: PubMed   Mentions: 5     Fields:    
    29. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016 06 10; 16:360. PMID: 27282289.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    30. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56. PMID: 27092812.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    31. Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. Arch Pathol Lab Med. 2016 11; 140(11):1250-1258. PMID: 27081877.
      View in: PubMed   Mentions: 9     Fields:    
    32. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression. Oncotarget. 2016 Mar 22; 7(12):13842-53. PMID: 26871599.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    33. RUNX1 prevents oestrogen-mediated AXIN1 suppression and ß-catenin activation in ER-positive breast cancer. Nat Commun. 2016 Feb 26; 7:10751. PMID: 26916619.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    34. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. PMID: 26884555.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    35. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. PMID: 26771938.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    36. Kidney transplantation in the Hispanic population. Clin Transplant. 2016 Feb; 30(2):118-23. PMID: 26529140.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63. PMID: 26567365.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables. J Surg Oncol. 2015 Aug; 112(2):125-32. PMID: 26171686.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    39. Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of Survival. Int J Gynecol Pathol. 2015 Jul; 34(4):379-84. PMID: 26061072.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab. 2015 Jul 07; 22(1):86-99. PMID: 26094889.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansAnimals
    41. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8. PMID: 25873574.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    42. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9. PMID: 25413313.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    43. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758. PMID: 25693195.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    44. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. PMID: 25695691.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    45. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. PMID: 25639769.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    46. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. PMID: 25278449.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    47. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging. 2014; 4(6):580-601. PMID: 25250207.
      View in: PubMed   Mentions:
    48. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7. PMID: 25125258.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    49. Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res. 2014 May 15; 74(10):2857-68. PMID: 24648349.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    50. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. PMID: 24099865.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    51. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother. 2013 Jun; 36(5):319-29. PMID: 23719242.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    52. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer. 2013 Feb 15; 119(4):756-65. PMID: 23319010.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    53. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012 Jul; 53(7):1155-63. PMID: 22700000.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    54. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 01; 18(9):2679-86. PMID: 22421195.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    55. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. PMID: 22198425.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    56. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS One. 2011; 6(12):e28141. PMID: 22163280.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    57. Human breast cancer histoid: an in vitro 3-dimensional co-culture model that mimics breast cancer tissue. J Histochem Cytochem. 2011 Dec; 59(12):1087-100. PMID: 22034518.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    58. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011 Jun; 2(2):77-84. PMID: 22811834.
      View in: PubMed   Mentions:
    59. A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs. Contemp Clin Trials. 2011 Sep; 32(5):694-703. Sposto R, Groshen S. PMID: 21554993.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    60. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res. 2011 Apr 15; 71(8):2848-57. Dong D, Stapleton C, Luo B, Xiong S, Ye W, Zhang Y, Jhaveri N, Zhu G, Ye R, Liu Z, Bruhn KW, Craft N, Groshen S, Hofman FM, Lee AS. PMID: 21467168.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    61. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer. 2011 Feb 01; 128(3):726-31. Lee E, Nichols P, Groshen S, Spicer D, Lee AS. PMID: 20473863.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    62. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. PMID: 20142723.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    63. Long-term outcome in patients with a Gleason score = 6 prostate cancer treated by radical prostatectomy. BJU Int. 2011 Sep; 108(5):660-4. Birkhahn M, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. PMID: 21223479.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    64. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010 Nov 01; 70(15):1692-700. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK. PMID: 20564320.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    65. A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010 Nov-Dec; 5(8):750-7. Bernstein I, Byun HM, Mohrbacher A, Douer D, Gorospe G, Hergesheimer J, Groshen S, O'Connell C, Yang AS. PMID: 20861661.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    66. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 2010 Oct 15; 16(20):5011-8. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ. PMID: 20876796.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansCells
    67. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 01; 70(12):1359-70. Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. PMID: 20623636.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    68. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis. 2010 Nov; 31(11):1964-71. Jiang X, Castelao JE, Yuan JM, Groshen S, Stern MC, Conti DV, Cortessis VK, Coetzee GA, Pike MC, Gago-Dominguez M. PMID: 20732908.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    69. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res. 2010 Sep 15; 16(18):4675-80. Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M, Cai J, Groshen S, Brands F, Engel J, Pinski J. PMID: 20670943.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    70. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. PMID: 20062993.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    71. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR. PMID: 20215558.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    72. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. PMID: 20215557.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    73. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics. 2009 Nov 30; 2:67. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. PMID: 19948057.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    74. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009 Nov 10; 27(32):5343-9. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK. PMID: 19805691.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    75. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol. 2010 Jan; 57(1):12-20. Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ. PMID: 19762144.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    76. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol. 2009 Aug 20; 27(24):3929-37. Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ. PMID: 19620494.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    77. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens. Anal Biochem. 2009 Sep 15; 392(2):117-25. Zon G, Barker MA, Kaur P, Groshen S, Jones LW, Imam SA, Boyd VL. PMID: 19505431.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    78. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol. 2009 Mar 10; 27(8):1290-6. Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. PMID: 19171709.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    79. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. PMID: 19213668.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    80. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med. 2008 Nov; 22(9):787-93. Jadvar H, Ye W, Groshen S, Conti PS. PMID: 19039557.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    81. J1-31 protein expression in astrocytes and astrocytomas. Neuropathology. 2009 Oct; 29(5):521-7. Shuangshoti S, Thorner PS, Ruangvejvorachai P, Saha B, Groshen S, Taylor CR, Malhotra S, Imam SA. PMID: 19019178.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    82. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone. Prostate. 2008 Nov 01; 68(15):1681-8. Saha B, Kaur P, Tsao-Wei D, Naritoku WY, Groshen S, Datar RH, Jones LW, Imam SA. PMID: 18712716.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    83. Water intake and bladder cancer risk in Los Angeles County. Int J Cancer. 2008 Oct 01; 123(7):1649-56. Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata DK, Conti DV, Gago-Dominguez M. PMID: 18623082.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    84. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res. 2008 Aug 01; 68(15):6208-14. Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, Cortessis VK, Tsao-Wei DD, Groshen S, Jones PA. PMID: 18676844.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    85. Guidelines for development of diagnostic markers in bladder cancer. World J Urol. 2008 Feb; 26(1):5-11. Goebell PJ, Groshen SL, Schmitz-Dräger BJ. PMID: 18253738.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    86. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. PMID: 18192902.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    87. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008 Jan 15; 68(2):498-505. Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, Mao C, Ye R, Wang M, Pen L, Dubeau L, Groshen S, Hofman FM, Lee AS. PMID: 18199545.
      View in: PubMed   Mentions: 162     Fields:    Translation:Animals
    88. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. PMID: 18165643.
      View in: PubMed   Mentions: 171     Fields:    Translation:HumansCTClinical Trials
    89. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. Prostate. 2008 Jan 01; 68(1):78-84. Saha B, Arase A, Imam SS, Tsao-Wei D, Naritoku WY, Groshen S, Jones LW, Imam SA. PMID: 18008331.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    90. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res. 2008 Jan-Feb; 28(1B):425-30. Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK. PMID: 18383880.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    91. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 2007 Dec 01; 25(34):5352-8. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA, Cote RJ. PMID: 18048815.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    92. Overexpression of E-cadherin protein in metastatic breast cancer cells in bone. Anticancer Res. 2007 Nov-Dec; 27(6B):3903-8. Saha B, Chaiwun B, Imam SS, Tsao-Wei DD, Groshen S, Naritoku WY, Imam SA. PMID: 18225549.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    93. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20; 25(24):3712-8. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. PMID: 17704420.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCTClinical Trials
    94. Alcohol consumption and risk of bladder cancer in Los Angeles County. Int J Cancer. 2007 Aug 15; 121(4):839-45. Jiang X, Castelao JE, Groshen S, Cortessis VK, Ross RK, Conti DV, Gago-Dominguez M. PMID: 17440923.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    95. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer. 2007 Nov; 58(2):220-30. Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA. PMID: 17659810.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    96. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol. 2007 Oct; 38(10):1547-52. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J. PMID: 17640713.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    97. Telomerase and markers of cellular proliferation are associated with the progression of cervical intraepithelial neoplasia lesions. Int J Gynecol Pathol. 2007 Jul; 26(3):214-22. Saha B, Chaiwun B, Tsao-Wei DD, Groshen SL, Naritoku WY, Atkinson RD, Taylor CR, Imam SA. PMID: 17581401.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    98. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol. 2007 Mar; 177(3):876-81; discussion 881-2. Stein JP, Penson DF, Cai J, Miranda G, Skinner EC, Dunn MA, Groshen S, Lieskovsky G, Skinner DG. PMID: 17296365.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    99. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response. BJU Int. 2007 May; 99(5):1024-7. Kang TY, Nichols P, Skinner E, Groshen S, Valin G, Ye W, Raghavan D. PMID: 17244277.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    100. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res. 2007 Jan 01; 13(1):215-22. Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS. PMID: 17200357.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    101. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. PMID: 17241515.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    102. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol. 2006 Nov; 176(5):2025-31; discussion 2031-2. Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG. PMID: 17070244.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    103. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006 Aug 15; 66(16):7849-53. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. PMID: 16912156.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    104. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol. 2006 Aug; 176(2):493-8; discussion 498-9. Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. PMID: 16813876.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    105. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics. 2006 Jul; 16(7):475-83. Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. PMID: 16788380.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    106. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18):2735-42. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ. PMID: 16782914.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    107. Comparisons of PCR-based genome amplification systems using CpG island microarrays. Hum Mutat. 2006 Jun; 27(6):589-96. Pike BL, Groshen S, Hsu YH, Shai RM, Wang X, Holtan N, Futscher BW, Hacia JG. PMID: 16652338.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    108. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology. 2006 Jun; 67(6):1247-52. Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. PMID: 16697447.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    109. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006 May 01; 106(9):2021-7. Chamberlain MC, Tsao-Wei DD, Groshen S. PMID: 16583432.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    110. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006 Jul; 78(3):271-6. Chamberlain MC, Tsao-Wei DD, Groshen S. PMID: 16628476.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    111. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer. 2006 Jan 01; 106(1):172-9. Chamberlain MC, Tsao-Wei DD, Groshen S. PMID: 16323194.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    112. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan; 7(1):67-88. Gordon MA, Gil J, Lu B, Zhang W, Yang D, Yun J, Schneider S, Groshen S, Iqbal S, Press OA, Rhodes K, Lenz HJ. PMID: 16354126.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    113. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005 Jul; 174(1):103-6. Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S, Daneshmand S, Skinner EC, Skinner DG. PMID: 15947587.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    114. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2005 Jul; 5(2):124-31. Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K, Groshen S, Lenz HJ. PMID: 16098254.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    115. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol. 2005 Jul; 174(1):93-6. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG. PMID: 15947585.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    116. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005 May 20; 23(15):3536-44. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. PMID: 15908664.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    117. Neoplastic meningitis-related encephalopathy. J Neurooncol. 2005 Apr; 72(2):185-9. Chamberlain MC, Tsao-Wei D, Groshen S. PMID: 15926000.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    118. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol. 2005 Apr; 173(4):1163-8. Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner DG. PMID: 15758728.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    119. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005 Mar; 200(3):336-44. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM, Danenberg PV. PMID: 15737843.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    120. Comparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarrays. Nucleic Acids Res. 2005 Feb 18; 33(3):e33. Karaman MW, Groshen S, Lee CC, Pike BL, Hacia JG. PMID: 15722479.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    121. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res. 2005 Feb 01; 11(3):1237-46. Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J. PMID: 15709194.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    122. Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):413-5. Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Grossman HB, Dinney CP, Waldman F, Cote RJ. PMID: 15701822.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    123. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):600-5. Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA, Vallböhmer D, Rhodes K, Lenz HJ. PMID: 15701846.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    124. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005 Feb 01; 23(4):741-50. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. PMID: 15613700.
      View in: PubMed   Mentions: 101     Fields:    Translation:HumansPHPublic Health
    125. Neoplastic meningitis-related encephalopathy: prognostic significance. Neurology. 2004 Dec 14; 63(11):2159-61. Chamberlain MC, Tsao-Wei D, Groshen S. PMID: 15596770.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    126. Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J Urol. 2004 Dec; 172(6 Pt 1):2182-6. Chang A, Cai J, Miranda G, Groshen S, Skinner D, Stein JP. PMID: 15538227.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    127. Association between monocyte Fcgamma subclass expression and acute coronary syndrome. Immun Ageing. 2004 Nov 12; 1(1):4. Calverley DC, Varteresian T, Brass E, Tsao-Wei DD, Groshen S, Mack WJ, Buchanan TA, Hodis HN, Schreiber AD. PMID: 15679933.
      View in: PubMed   Mentions:
    128. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol. 2004 Oct; 155(1-2):161-71. Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, Gilmore W, Cheema GS, Stohl W, Burnett ME, Ko D, Kachuck NJ, Weiner LP. PMID: 15342208.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    129. Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder. J Urol. 2004 Jul; 172(1):81-4. Daneshmand S, Stein JP, Lesser T, Quek ML, Nichols PW, Miranda G, Cai J, Groshen S, Skinner EC, Skinner DG. PMID: 15201742.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    130. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer. Anticancer Res. 2004 Jul-Aug; 24(4):2391-400. Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA. PMID: 15330189.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol. 2004 Jul-Aug; 22(4):277-84. Goebell PJ, Groshen S, Schmitz-Dräger BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Barton Grossman H, Waldman F, Cote RJ. PMID: 15283883.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    132. Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab Invest. 2004 Jun; 84(6):667-78. Bu X, Khankaldyyan V, Gonzales-Gomez I, Groshen S, Ye W, Zhuo S, Pons J, Stratton JR, Rosenberg S, Laug WE. PMID: 15094713.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    133. Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients. Obstet Gynecol. 2004 Jun; 103(6):1204-10. Lentz SE, Muderspach LI, Felix JC, Ye W, Groshen S, Amezcua CA. PMID: 15172853.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    134. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004 Apr 13; 62(7):1210-2. Chamberlain MC, Tsao-Wei DD, Groshen S. PMID: 15079029.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    135. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004 Mar 01; 64(5):1675-86. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA. PMID: 14996727.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    136. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004 Mar 15; 22(6):1007-13. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. PMID: 14981105.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    137. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. PMID: 14713777.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    138. Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer. 2004 Jan 23; 3:5. Pagliarulo V, George B, Beil SJ, Groshen S, Laird PW, Cai J, Willey J, Cote RJ, Datar RH. PMID: 14741054.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    139. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. PMID: 12942562.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    140. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003 Jul; 170(1):35-41. Stein JP, Cai J, Groshen S, Skinner DG. PMID: 12796639.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    141. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol. 2003 Apr; 121(1):139-42. Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, Groshen S. PMID: 12670344.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    142. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003 Apr; 9(4):1301-12. Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. PMID: 12684398.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    143. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol. 2003 Mar; 1(3):162-6. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ. PMID: 16224397.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    144. Establishment of a nude mouse model of hepatic metastasis for evaluation of targeted retroviral gene delivery. J Surg Oncol. 2003 Feb; 82(2):121-30; discussion 131. Stapfer M, Hu J, Wei D, Groshen S, Beart RW. PMID: 12561068.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    145. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan; 9(1):223-7. Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV, Takebe N, Schneider S, Hölscher AH, Danenberg KD, Danenberg PV. PMID: 12538473.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    146. P7 antigen expression in human breast cancer. Clin Cancer Res. 2003 Jan; 9(1):201-6. Yang X, Groshen S, Formenti SC, Davidson NE, Press MF. PMID: 12538470.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    147. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem. 2002 Dec 20; 277(51):49531-7. Erdreich-Epstein A, Tran LB, Bowman NN, Wang H, Cabot MC, Durden DL, Vlckova J, Reynolds CP, Stins MF, Groshen S, Millard M. PMID: 12388538.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    148. Potential role of platelet FcgammaRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis. 2002 Oct; 164(2):261-7. Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, Hodis HN, Groshen S. PMID: 12204796.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    149. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ. Anticancer Res. 2002 Sep-Oct; 22(5):2933-7. Baltayan A, Naritoku WY, Chaiwun B, Tsao-Wei DD, Groshen S, Hern RA, Gusterson BA, Taylor CR, Imam SA. PMID: 12530020.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    150. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 2002 Aug; 67(9):799-813. Press M, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP. PMID: 12123792.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    151. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2002 Jun 19; 94(12):936-42. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ. PMID: 12072547.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    152. The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):438-43. Brabender J, Danenberg KD, Metzger R, Schneider PM, Lord RV, Groshen S, Tsao-Wei DD, Park J, Salonga D, Hölscher AH, Danenberg PV. PMID: 11839661.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    153. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2002 Feb 01; 52(2):397-405. Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. PMID: 11872285.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    154. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis. 2002 Jan; 17(1):46-9. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. PMID: 12018454.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    155. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma. Anticancer Res. 2000 May-Jun; 20(3A):1451-61. Liu D, Baltayan A, Naritoku WY, Barr NJ, Young LL, Chaiwun B, Tsao-Wei DD, Groshen SL, Taylor CR, Torloni H, Neville AM, Cote RJ, Imam SA. PMID: 10928056.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    156. Telomerase activity: comparison between fine-needle aspiration and biopsy specimens for the detection of tumor cells. Cancer. 1999 Aug 25; 87(4):210-5. Naritoku WY, Datar RH, Li P, Groshen SL, Taylor CR, Imam SA. PMID: 10455209.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    157. The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services. Am J Health Syst Pharm. 1998 Dec 01; 55(23):2485-99. McCombs JS, Liu G, Shi J, Feng W, Cody M, Parker JP, Nichol MB, Hay JW, Johnson KA, Groshen SL, Nye MT. PMID: 9853633.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    158. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993 Apr; 149(4):758-64; discussion 764-5. Lerner SP, Skinner DG, Lieskovsky G, Boyd SD, Groshen SL, Ziogas A, Skinner E, Nichols P, Hopwood B. PMID: 8455238.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans